Shanghai Haohai Biological Technology Co., Ltd. submitted a Next Day Disclosure Return on 07 November 2025. According to the announcement, the company’s total issued H shares stood at 38,529,240, unchanged from the previous balance. The company also maintained 190,203,760 A shares and 3,848,095 A treasury shares, making a total of 194,051,855 A shares as of 07 November 2025.

The announcement stated that multiple batches of H shares were repurchased from 15 September 2025 through 07 November 2025 but not yet canceled, with a recent batch of 53,100 shares repurchased on 07 November 2025 at an aggregate price paid of HKD 1,461,846. In total, 440,000 shares had been repurchased under an existing mandate authorized on 10 June 2025, accounting for 1.1241% of the company’s issued shares (excluding treasury shares) at the time of that authorization.

It was further reported that, following the latest repurchase, no immediate changes to the number of issued H shares or A shares occurred as of 07 November 2025. A 30-day moratorium on new share issuance or treasury share sales remains in effect until 07 December 2025.